Journey of a Novice Investor…
1. Investment Thesis & Executive Summary The “Deep Value” Argument: A Historic Dislocation Far East Consortium International Limited (FEC) represents a paradigmatic example of market dislocation within the Hong Kong-listed real estate sector. As of late November 2025, the equity trades at approximately HK$0.70 per share against an Adjusted Net Asset Value (NAV) estimated at … Read more
1. Executive Summary Investment Thesis: Asymmetric Risk/Reward in a “Net-Net” Scenario China Starch Holdings Limited (3838.HK) currently represents a classic, textbook “Graham-and-Dodd” deep value opportunity, characterized by a profound dislocation between its market capitalization and its liquid asset backing. Trading at HK$ 0.18 against a Net Cash position of approximately HK$0.31 per share, the market … Read more
1. Executive Summary 1.1 The Investment Thesis: A Bifurcated Growth Engine Ticker: 0799.HK Reference Price: HK$ 3.79 (25 November 2025) Market Capitalization: HK$ 4.349 Billion (25 November 2025) IGG Inc (“IGG” or “the Group”) presents a compelling investment opportunity characterized by a rare convergence of deep value, substantial dividend yield, and a credible, data-supported turnaround … Read more
1. Executive Summary The Strategic Pivot: From Localized Tradition to Modern Casual Ticker: 2660.HK Reference Price: HK$ 2.30 (25 November 2025) Market Capitalization: HK$ 2.379 billion (25 November 2025) Zengame Technology Holding Limited (“Zengame” or the “Group”) is currently navigating one of the most consequential strategic transitions in its corporate history. Established as a dominant … Read more
1. Executive Summary Investment Thesis: A Fortress Balance Sheet with a Free Call Option on Growth PW Medtech Group Limited (“PW Medtech” or the “Group”) currently presents one of the most pronounced dislocations between intrinsic asset value and market capitalization within the Hong Kong healthcare small-cap sector. Trading at a market capitalization of HK$ 1.975 … Read more
Ticker: 06896.HK (Hong Kong Stock Exchange) Sector: Consumer Healthcare / Traditional Chinese Medicine (TCM) Current Price: HK$ 3.43 (24 November 2025) Market Capitalization: HK$ 2.54 Billion (24 November 2025) 1. Executive Summary Investment Thesis: The Volatility of a Cash-Rich Niche Leader Golden Throat Holdings Group Company Limited (“Golden Throat” or “the Group”) presents a singularly … Read more
1. Executive Summary The Investment Thesis: Arbitrage in Plain Sight The comprehensive analysis of Automated Systems Holdings Limited (“ASL” or “the Group”) reveals a profound valuation dislocation within the Hong Kong Technology, Media, and Telecom (TMT) sector. As of late 2025, the market is pricing ASL at a level that implies a negative enterprise value … Read more
1. Executive Summary & Investment Thesis Link Real Estate Investment Trust (“Link REIT” or “The Group”) stands at a pivotal juncture in its twenty-year history. As Asia’s largest Real Estate Investment Trust by market capitalization, Link serves as a primary bellwether for the Hong Kong commercial property sector and, by extension, the broader health of … Read more
1. Executive Summary & Key Metrics Fufeng Group Limited (0546.HK) represents a compelling deep-value and high-yield opportunity. As a global leader in the bio-fermentation industry, the company’s stock trades at a significant discount to both its intrinsic value and its primary peers. This valuation gap, evidenced by a Price-to-Book ratio of approximately 0.96x, is driven … Read more
1. Executive Summary & Key Metrics Far East Horizon Limited (“FE Horizon” or “the Company”) represents an attractive, albeit complex, investment opportunity. It is a hybrid “Finance + Industry” conglomerate, not a pure-play financial leasing firm. The market, however, appears to be valuing it as a distressed, high-risk, low-growth Chinese financial institution, as evidenced by … Read more